Special Issue "Breast Cancer Imaging and Therapy"

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".

Deadline for manuscript submissions: 1 April 2022.

Special Issue Editor

Prof. Dr. Jean Seely
E-Mail Website
Guest Editor
Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada
Interests: breast cancer screening; high-risk screening; breast MRI

Special Issue Information

Dear Colleagues,

In Canada, survival from breast cancer has steadily increased since 1989, and breast cancer mortality has decreased by 48% [1]. While 82% of women with breast cancer are diagnosed at stage 1 or 2, there are still 18% who present at a late stage and 25% who develop metastatic disease. Improved survival has been achieved through early diagnosis of breast cancer with screening, allowing more effective and targeted treatments. Significant gaps remain, however, where an early diagnosis of breast cancer in certain populations is not achieved, including women with dense breasts, those of Black (African), Asian, Indigenous, and Hispanic ethnicities, women aged 40–49 years not included in screening mammography programs, women at high risk who are 30 years and older, and men. We invite submissions of manuscripts to summarize the latest evidence on early detection of breast cancer and highlight areas where this may be improved. 

Original research and reviews are welcome. Research areas may include (but are not limited to) the following: radiology, epidemiology, ethicists, and public health.

Prof. Dr. Jean Seely
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer screening
  • dense breast tissue
  • disparities

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Contrast-Enhanced Spectral Mammography Assessment of Patients Treated with Neoadjuvant Chemotherapy for Breast Cancer
Curr. Oncol. 2021, 28(5), 3448-3462; https://doi.org/10.3390/curroncol28050298 - 06 Sep 2021
Viewed by 370
Abstract
Background: Evaluating the tumor response to neoadjuvant chemotherapy is key to planning further therapy of breast cancer. Our study aimed to evaluate the effectiveness of low-energy and subtraction contrast-enhanced spectral mammography (CESM) images in the detection of complete response (CR) for neoadjuvant chemotherapy [...] Read more.
Background: Evaluating the tumor response to neoadjuvant chemotherapy is key to planning further therapy of breast cancer. Our study aimed to evaluate the effectiveness of low-energy and subtraction contrast-enhanced spectral mammography (CESM) images in the detection of complete response (CR) for neoadjuvant chemotherapy (NAC) in breast cancer. Methods: A total of 63 female patients were qualified for our retrospective analysis. Low-energy and subtraction CESM images just before the beginning of NAC and as a follow-up examination 2 weeks before the end of chemotherapy were compared with one another and assessed for compliance with the postoperative histopathological examination (HP). The response to preoperative chemotherapy was evaluated based on the RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Results: Low-energy images tend to overestimate residual lesions (6.28 mm) and subtraction images tend to underestimate them (2.75 mm). The sensitivity of low-energy images in forecasting CR amounted to 33.33%, while the specificity was 92.86%. In the case of subtraction CESM, the sensitivity amounted to 85.71% and the specificity to 71.42%. Conclusions: CESM is characterized by high sensitivity in the assessment of CR after NAC. The use of only morphological assessment is insufficient. CESM correlates well with the size of residual lesions on histopathological examination but tends to underestimate the dimensions. Full article
(This article belongs to the Special Issue Breast Cancer Imaging and Therapy)
Show Figures

Figure 1

Back to TopTop